Clinical-stage biotech Enliven Therapeutics reported Q2 2025 results, highlighting positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia and a strengthened cash position of $490.5 million following a $230 million public offering.

Enliven Therapeutics (ELVN) is a good choice for trend investors due to its recent price increase, positive earnings estimate revisions, and strong fundamentals, making it a Zacks Rank #2 (Buy) stock.

Enliven Therapeutics reported positive data from a Phase 1 trial of its drug ELVN-001for chronic myeloid leukemia, with a 44% major molecular response rate by 24 weeks and a favorable safety profile.

Anish Patel, the Chief Operating Officer of Enliven Therapeutics, has sold over $1.25 million worth of company stock in a series of transactions. The sales were conducted under a Rule 10b5-1 trading plan, and Patel remains a significant shareholder in the company.

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:

Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance. Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement. Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company. Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof ...

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia. Enliven Therapeutics shares surged 26% to $24.97 on Thursday. Here are some other big stocks recording losses in today’s session. Rallybio Corporation (NASDAQ: RLYB) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Alpine Immune Sciences, ...

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.

Mizuho Securities initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN), a clinical-stage precision oncology company focused on discovering and developing next-generation small molecule kinase inhibitors. The company’s lead product, ELVN-001, is under development for Chronic myelogenous leukemia (CML), a slow-progressing blood cancer that begins in the bone marrow. Thursday, Enliven Therapeutics will host a webcast to discuss initial proof of concept data on ELVN-001. Additional Phase 1 data is expected in 2025, but Mizuho expects late 2024 could also be possible. Mizuho writes that the CML tyrosine kinase inhibitors (TKI) market is established, ~$13 billion-$14 ...Full story available on Benzinga.com

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape. ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.